RESPONSE TO BLOCKADE OF THE INHIBITORY IMMUNE CHECKPOINT TIGIT PROMOTES ANTI-TUMOR IMMUNITY IN MULTIPLE MYELOMA

EHA Library, Carlos Fernández de Larrea, 294787

EXOME SEQUENCING OF MULTIPLE MYELOMA RESIDUAL CELLS: TOWARDS IDENTIFICATION OF DRUGGABLE TARGETS FOR PERSONALIZED TREATMENT

EHA Library, Martina Zátopková, 294788

BLOCKING OF TRANSIENT RECEPTOR POTENTIAL VANILLOID1 (TRPV1) PROMOTES TERMINAL MITOPHAGY IN MULTIPLE MYELOMA, DISTURBING CALCIUM HOMEOSTASIS AND TARGETING UBIQUITIN PATHWAY AND BORTEZOMIB-INDUCED UPR

EHA Library, Katia Beider, 294789

EXPRESSION LEVELS OF P53 MRNA ISOFORMS REFINE PROGNOSIS IN MULTIPLE MYELOMA

EHA Library, Elizabeta A. Rojas, 294791

CELL-FREE DNA ANALYSIS FOR THE DETECTION OF MYD88 AND CXCR4 MUTATIONS IN IGM MONOCLONAL GAMMOPATHIES; AN UPDATE WITH CLINICOPATHOLOGICAL CORRELATIONS

EHA Library, Ioannis Ntanasis-Stathopoulos, 294793

THE ROLE OF VASCULAR PHENOTYPE IN THE DEVELOPMENT OF CARFILZOMIB-INDUCED HYPERTENSION

EHA Library, Panagiotis Efentakis, 294795

USEFULNESS OF CIRCULATING CELL-FREE DNA TO DEFINE HOW MULTIPLE MYELOMA SPREAD AND DISSEMINATE THROUGHOUT THE BONE MARROW IN NEWLY DIAGNOSED PATIENTS

EHA Library, Marina Martello, 294796

SINGLE PLASMA CELL TRANSCRIPTOME ANALYSIS IN POEMS SYNDROME

EHA Library, Yusuke Isshiki, 294797

IRON TRAFFICKING PROMOTES BORTEZOMIB RESISTANCE IN MULTIPLE MYELOMA

EHA Library, Alessandro Barbato, 294799

BIALLELIC DELETION OF CHROMOSOME 16P ENCOMPASSING THE BCMA LOCUS AS A TUMOR-INTRINSIC RESISTANCE MECHANISM TO BCMA-DIRECTED CAR T IN MULTIPLE MYELOMA

EHA Library, Leo Rasche, 294800

SUPERIOR ANTI-TUMOR ACTIVITY OF HEXABODY®-CD38 IN PRECLINICAL MODELS OF MULTIPLE MYELOMA, B CELL LYMPHOMA AND ACUTE MYELOID LEUKEMIA

EHA Library, Ida H. Hiemstra, 294801

LNCRNAS AS NOVEL PARTNERS OF FUSION TRANSCRIPTS IN MULTIPLE MYELOMA

EHA Library, Ane Amundarain, 294802

GERMLINE PREDICTORS OF IMMUNE DYSREGULATION IN MULTIPLE MYELOMA

EHA Library, Moritz Binder, 294803

CHARACTERIZATION OF GSK2606414, A SELECTIVE AND POTENT PERK INHIBITOR WITH EFFICACY IN MULTIPLE MYELOMA

EHA Library, Tina Bagratuni, 294804

NKTR-255 AS A NOVEL IMMUNOTHERAPEUTIC APPROACH TO RESTORE INNATE AND ADAPTIVE IMMUNE REPERTOIRE IN MULTIPLE MYELOMA

EHA Library, Rafael Alonso Fernández, 294805

NELFINAVIR INHIBITS PROTEASOME RE-SYNTHESIS IN MULTIPLE MYELOMA: THE TCF11/NRF1 PATHWAY AS A THERAPEUTIC TARGET

EHA Library, František Sedlák, 294806

RNA AND DNA SEQUENCING REVEAL MARKERS OF RESPONSE TO THE XPO1 INHIBITOR ELTANEXOR IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)

EHA Library, Christopher Walker, 294807

MULTIPLE MYELOMA PATIENTS CARRY A SUBSTANTIAL NUMBER OF POTENTIALLY HARMFUL GERMLINE VARIANTS

EHA Library, Marja Hakkarainen, 294808

NR2F1 GENE REGULATES MACROPHAGE POLARIZATION IN MULTIPLE MYELOMA DRUG RESISTANCE

EHA Library, Danfeng Zhang, 294809

PERIPHERAL BLOOD IMMUNE PROFILING OF MULTIPLE MYELOMA PATIENTS AT DIAGNOSIS; CORRELATIONS WITH CIRCULATING PLASMA CELLS

EHA Library, Evangelos Terpos, 294810

PHARMACODYNAMIC RESPONSES DRIVE DOSE/SCHEDULE SELECTION OF CC-92480, A NOVEL CELMOD AGENT, IN A PHASE 1 DOSE-ESCALATION STUDY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Lilly Wong, 294811

THE NOVEL CELMOD AGENT CC-92480: TRANSLATION OF PRECLINICAL DATA TO A PHASE 1 CLINICAL TRIAL DESIGN

EHA Library, Lilly Wong, 294812

INHIBITION OF S100A9 WITH TASQUINIMOD DEMONSTRATES POTENT ANTI-TUMOR ACTIVITY IN PRE-CLINICAL MODELS OF MULTIPLE MYELOMA

EHA Library, Cindy Lin, 294813

AMINOPEPTIDASE EXPRESSION IN MULTIPLE MYELOMA ASSOCIATES WITH DISEASE PROGRESSION AND SENSITIVITY TO MELFLUFEN

EHA Library, Juho Miettinen, 294814

IMPACT OF AGING AND HYPERLIPIDAEMIA ON METFORMIN CARDIOPROTECTION AGAINST CARFILZOMIB-INDUCED CARDIOTOXICITY IN VIVO

EHA Library, Panagiotis Efentakis, 294815

COMPLEMENT C3A ACTIVATES OSTEOCLASTS BY REGULATING THE PI3K/PDK1/SGK3 PATHWAY IN PATIENTS WITH MULTIPLE MYELOMA

EHA Library, Rong Fu, 294816

RNA DEMETHYLASE ALKBH5 PROMOTED TUMORIGENESIS VIA REGULATING HIPPO SIGNAL PATHWAY AND MYELOMA STEM CELL IN MULTIPLE MYELOMA

EHA Library, Yu Tingting, 294817

STUDY ON METHYLATION OF RAS ASSOCIATION DOMAIN FAMILY 10 GENE PROMOTER IN MULTIPLE MYELOMA

EHA Library, Rong Fu, 294818

THE ASSOCIATION OF CALCIUM BINDING PROTEINS S100A8 AND S100A9 WITH DRUG RESPONSE IN MULTIPLE MYELOMA

EHA Library, Minxia Liu, 294819

MELFLUFEN EFFICACY IN MULTIPLE MYELOMA WITH TP53 ABERRATIONS

EHA Library, Ana Slipicevic, 294820

INNATE CD8 T-CELLS AND INKT LYMPHOCYTES IN MONOCLONAL GAMMOPATHY

EHA Library, Cécile Gruchet, 294821

THE ADAPTIVE RESPONSE TO TRYPTOPHAN DEPRIVATION PERTURBS CD38 EXPRESSION AND MITOCHONDRIAL NETWORK TO PRESERVE AVAILABILITY OF INTRACELLULAR NAD+

EHA Library, Alessandra Romano, 294822

SELECTIVE KILLING MULTIPLE MYELOMA CELLS BY TARGETING FREE LIGHT CHAIN SECRETION, ENDOPLASMIC RETICULUM STRESS AND UNFOLDED PROTEIN RESPONSE USING THE COMBINATION OF VALPROATE AND NICLOSAMIDE (VAN)

EHA Library, Yao Jiang, 294823

MALDI-TOF MASS SPECTROMETRY IN SERUM FOR THE FOLLOW-UP OF NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH DARATUMUMAB-BASED COMBINATION THERAPY

EHA Library, Marion Eveillard, 294824

THE ROLE OF MICRORNAS IN THE PATHOGENESIS OF AL AMYLOIDOSIS

EHA Library, Hila Fishov, 294825

ANALYSIS OF SERUM CELL-FREE DNA IN MULTIPLE MYELOMA WITH OVEREXPRESSION OF MAF FAMILY GENES

EHA Library, Takuto Tachita, 294826

COMBINED INHIBITION OF XPO1 AND EIF4E PREVENTS PROTEIN TRANSLATION AND HAS SYNERGISTIC ANTI-MYELOMA EFFECTS

EHA Library, Shirong Li, 294827

PD-1- AND TIM-3-EXPRESSING T CELLS INCREASE PROLIFERATIVE ABILITY AND PARTIALLY RETAIN FUNCTIONAL PROPERTIES AT EARLY POST-TRANSPLANT PERIOD IN MULTIPLE MYELOMA PATIENTS

EHA Library, Egor Batorov, 294828

DETECTION OF PHENOTYPICAL CLONAL EVOLUTION BY MULTI-DIMENSIONAL FLOW CYTOMETRY AFTER THE FIRST LINE TREATMENT IN PATIENTS DIAGNOSED WITH MULTIPLE MYELOMA

EHA Library, Elena Paumard Rodríguez, 294829

PROTEIN KINASE CK1ALPHA CONTROLS PLASMA CELLS AND STROMAL CELLS RUNX2 EXPRESSION POTENTIALLY AFFECTING THE MULTIPLE MYELOMA-ASSOCIATED BONE DISEASE

EHA Library, Anna Fregnani, 294830

AUTOLOGOUS NK CELL-BASED IMMUNOTHERAPY FOR MAINTENANCE TREATMENT OF MULTIPLE MYELOMA

EHA Library, Hareth Nahi, 294831

MELFLUFEN IS A HIGHLY EFFECTIVE ANTI-NEOPLASTIC AGENT IN BORTEZOMIB-RESISTANT MULTIPLE MYELOMA MODELS

EHA Library, Konstantin Byrgazov, 294832

FLOWCT: A SEMI-AUTOMATED WORKFLOW FOR DECONVOLUTION OF IMMUNOPHENOTYPIC DATA AND OBJECTIVE REPORTING ON LARGE DATASETS

EHA Library, Catarina Maia, 294833

EXPRESSION SIGNIFICANCE OF CRL4-CRBN PROTEINS COMPLEX IN MULTIPLE MYELOMA PATIENTS TREATED WITH IMMUNOMODULATORY DRUGS.

EHA Library, Joanna Barankiewicz, 294834

SOLITARY PLASMOCYTOMA CAN BE STRATIFIED BY NEXT GENERATION SEQUENCING

EHA Library, Marguerite Vignon, 294835

A SAME DAY CYTOCHROME C RELEASE ASSAY PREDICTS APOPTOTIC RESPONSE TO COMBINED BCL-2/MCL-1 BH3 MIMETIC TARGETING IN MULTIPLE MYELOMA CELLS

EHA Library, Martin Grundy, 294836

SOMATIC MUTATIONS IN RAS GENES ARE ASSOCIATED WITH POOR PROGNOSIS IN MULTIPLE MYELOMA

EHA Library, Anna Sergeeva, 294837

LICOCHALCONE A IS A NOVEL SP1 INHIBITOR WITH STRONG ANTI-MYELOMA ACTIVITY

EHA Library, Hua Bai, 294838

EVALUATION OF THE PROGNOSTIC ROLE OF THE BONE MARROW MULTIPARAMETER FLOW CYTOMETRY (MFC) IN NEW DIAGNOSED LIGHT CHAIN AMYLOIDOSIS (AL)

EHA Library, Danilo De Novellis, 294839

A POLYGENIC RISK SCORE FOR MULTIPLE MYELOMA RISK PREDICTION

EHA Library, Angelica Macauda, 294840

REAL TIME GENOMIC AND TRANSCRIPTOMIC PROFILING ALLOWS RAPID STRATIFICATION OF MULTIPLE MYELOMA

EHA Library, Anna Dolnik, 294841

IDENTIFICATION OF CIRCULATING PLASMA CELLS IN MULTIPLE MYELOMA, MGUS AND SMOULDERING MYELOMA BY FLOW CYTOMETRY, USING A SINGLE PLATFORM-QUANTITATIVE METHOD

EHA Library, Giulia Micol Morocutti, 294842

TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA WITH JNJ-4528, A B-CELL MATURATION ANTIGEN (BCMA)-DIRECTED CHIMERIC ANTIGEN RECEPTOR (CAR)-T CELL THERAPY: UPDATE OF PHASE 1B RESULTS FROM CARTITUDE-1

EHA Library, Saad Z. Usmani, 294843

ORVACABTAGENE AUTOLEUCEL (ORVA-CEL), A B-CELL MATURATION ANTIGEN-DIRECTED CAR T CELL THERAPY FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATE OF THE PHASE 1/2 EVOLVE STUDY

EHA Library, Sham Mailankody, 294844

DARATUMUMAB, CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE (DARA-KRD) INDUCTION, AUTOLOGOUS TRANSPLANTATION AND MRD RESPONSE-ADAPTED CONSOLIDATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA

EHA Library, Luciano J. Costa, 294845

EFFICACY AND TOLERABILITY OF INDUCTION TREATMENT WITH IXAZOMIB, DARATUMUMAB AND LOW-DOSE DEXAMETHASONE IN FRAIL NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS – RESULTS OF THE PHASE II HOVON 143 TRIAL

EHA Library, Claudia A.M. Stege, 294846

A PHASE 1B STUDY OF TAK-079, AN INVESTIGATIONAL ANTI-CD38 MONOCLONAL ANTIBODY (MAB) IN PATIENTS WITH RELAPSED/ REFRACTORY MULTIPLE MYELOMA (RRMM): PRELIMINARY RESULTS

EHA Library, Amrita Krishnan, 294848

UNDETECTABLE MEASURABLE RESIDUAL DISEASE (MRD) AS ENDPOINT OF MAINTENANCE THERAPY: RESULTS FROM THE TOURMALINE-MM3 TRIAL OF IXAZOMIB VS PLACEBO MAINTENANCE IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)

EHA Library, Bruno Paiva, 294849

A NEW RISK STRATIFICATION STRATEGY IN NEWLY DIAGNOSED MULTIPLE MYELOMA: AN ANALYSIS ON MATURE DATA FROM EUROPEAN CLINICAL TRIALS WITHIN THE HARMONY BIG DATA PLATFORM

EHA Library, Mattia D'Agostino, 294850

A PHASE 2 STUDY OF BELANTAMAB MAFODOTIN (GSK2857916) IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FOR PART 1 DOSE FINDING

EHA Library, Suzanne Trudel, 294851

COMBINED INFUSION OF ANTI-CD19 AND ANTI-BCMA CAR-T CELLS AFTER ASCT IN THE FRONT LINE WAS SUPERIOR TO SINGLE ASCT FOR HIGH RISK MM

EHA Library, Xiaolan Shi, 294852

HOW TO DEFINE AND PREDICT UNSUSTAINED CR IN TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA: A SUB ANALYSIS OF THE GEM2012MENOS65 TRIAL

EHA Library, Ana Jiménez Ubieto, 294853

DREAMM-2: SINGLE-AGENT BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) – OUTCOMES BY PRIOR THERAPIES

EHA Library, Sagar Lonial, 294854

CARFILZOMIB, DEXAMETHASONE (KD) AND DARATUMUMAB VERSUS KD IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSIS OF THE CANDOR STUDY BY NUMBER OF PRIOR LINES OF THERAPY AND PRIOR THERAPIES

EHA Library, Katja Weisel, 294855

UPDATED RESULTS FROM BELLINI, A PHASE 3 STUDY OF VENETOCLAX OR PLACEBO IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Shaji K. Kumar, 294856

UPDATED RESULTS FROM A PHASE 1/2 STUDY OF VENETOCLAX IN COMBINATION WITH DARATUMUMAB AND DEXAMETHASONE, +/- BORTEZOMIB, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Jonathan L. Kaufman, 294857

High Levels of Circulating Plasma Cells Predict Low Rate of Sustained Minimal Residual Disease Negativity in Transplant Eligible Multiple Myeloma Patients Treated with Novel Agents

EHA Library, Luca Bertamini, 294858

S-ERMM: A SIMPLIFIED SCORE TO PREDICT EARLY RELAPSE IN NEWLY DIAGNOSED MULTIPLE MYELOMA. ANALYSIS FROM A POOLED DATASET OF 2190 PATIENTS.

EHA Library, Gian Maria Zaccaria, 294859

COMPARISON OF NEXT GENERATION SEQUENCING AND NEXT GENERATION FLOW KEY METRICS IN MULTIPLE MYELOMA MRD ASSESSMENT: DATA FROM THE GMMG HD6 TRIAL

EHA Library, Katharina Kriegsmann, 294860

PROGNOSTIC IMPACT OF TRISOMIES WITH 1Q GAIN OR 13Q DELETION BY FISH IN PATIENTS WITH SYSTEMIC LIGHT CHAIN AMYLOIDOSIS

EHA Library, Harsh Parmar, 294861

HORIZON (OP-106): MELFLUFEN PLUS DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) REFRACTORY TO POMALIDOMIDE AND/OR AN ANTI-CD38 MONOCLONAL ANTIBODY – PRIMARY AND SUBGROUP ANALYSIS

EHA Library, PAUL RICHARDSON, 294862

QIP-MASS SPECTROMETRY INCLUDING FREE LIGHT CHAINS IN HIGH-RISK MYELOMA PATIENTS ENROLLED IN THE GEM-CESAR TRIAL: COMPARISON WITH CONVENTIONAL AND MRD DISEASE IMWG RESPONSE ASSESSMENT

EHA Library, Noemi Puig, 294863

DARATUMUMAB + BORTEZOMIB, THALIDOMIDE, AND DEXAMETHASONE (D-VTD) IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: BASELINE SLIMCRAB-BASED SUBGROUP ANALYSIS OF CASSIOPEIA

EHA Library, Cyrille Touzeau, 294864

SAFETY AND TOLERABILITY OF SINGLE-AGENT BELANTAMAB MAFODOTIN IN HEAVILY PRE-TREATED PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: POOLED DATA FROM DREAMM-1 AND DREAMM-2

EHA Library, Suzanne Trudel, 294865

PHASE II CLINICAL TRIAL (EMN-ALLORIC 2010) OF ALLOGENEIC STEM CELL TRANSPLANTATION (ALLOSCT) FOR HIGH RISK (HR) MULTIPLE MYELOMA (MM).

EHA Library, Marta Reinoso Segura, 294866

OVER TEN YEARS OF F/U FOR PHASE 3 TRIAL IN SMOLDERING MYELOMA AT HIGH RISK OF PROGRESSION TO MYELOMA: SUSTAINED TTP AND OS BENEFIT WITH RD VERSUS NO TREATMENT

EHA Library, María-Victoria Mateos, 294867

REAL-WORLD MANAGEMENT OF PATIENTS WITH SYSTEMIC LIGHT CHAIN AMYLOIDOSIS IN EUROPE: A RETROSPECTIVE OBSERVATIONAL MULTICENTER STUDY BY EUROPEAN MYELOMA NETWORK (EMN)

EHA Library, Efstathios Kastritis, 294868

IMPACT OF DARATUMUMAB IN THE TREATMENT OF MULTIPLE MYELOMA ACCORDING TO CYTOGENETIC RISK

EHA Library, Luciano J. Costa, 294869

PHASE I, OPEN-LABEL STUDY OF PANOBINOSTAT, LENALIDOMIDE, BORTEZOMIB + DEXAMETHASONE IN RELAPSED AND RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Jacob P. Laubach, 294870

HYPOGAMMAGLOBINEMIA AND INCREASED INFECTION RATES ASSOCIATED WITH DARATUMUMAB THERAPY IN MULTIPLE MYELOMA: WORSE WITH -PROTEASOME INHIBITOR COMPARED TO IMID-BASED COMBINATIONS

EHA Library, Roy Vitkon, 294871

DREAMM-4: EVALUATING SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

EHA Library, Ajay Nooka, 294872

A SIMPLE SCORE TO PREDICT EARLY SEVERE INFECTION RISK IN PATIENTS WITH MULTIPLE MYELOMA TRANSPLANT AND NON-TRANSPLANT CANDIDATES

EHA Library, Cristina Encinas, 294873

OPTIMISMM SUBANALYSIS: POMALIDOMIDE, BORTEZOMIB, DEXAMETHASONE AFTER 1 PRIOR LINE OF THERAPY IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA BY AGE, PRIOR TRANSPLANT, AND HIGH-RISK CYTOGENETICS

EHA Library, Meletios Dimopoulos, 294874

AUTOLOGOUS STEM CELL TRANSPLANTATION VERSUS NO TRANSPLANTATION IN PATIENTS ABOVE 70 WITH MULTIPLE MYELOMA

EHA Library, Christopher Lemieux, 294875

BASELINE AND POSTINFUSION PHARMCODYNAMIC BIOMARKERS OF SAFETY AND EFFICACY IN PATIENTS TREATED WITH IDECABTAGENE VICLEUCEL (IDE-CEL; BB2121) IN THE KARMMA STUDY

EHA Library, Justine Dell’Aringa, 294876

MULTIPARAMETER FLOW CYTOMETRY (MFC) AND NEXT GENERATION SEQUENCING (NGS) FOR MINIMAL RESIDUAL DISEASE (MRD) EVALUATION: RESULTS OF THE FORTE TRIAL IN NEWLY DIAGNOSED MULTIPLE MYELOMA (MM)

EHA Library, Stefania Oliva, 294877

CARFILZOMIB IN COMBINATION WITH EITHER RD OR TD OVERCOMES THE NEGATIVE IMPACT OF HR CYTOGENETICS IN NDMM. INTERIM EFFICACY ANALYSIS OF COMBINED DATA OF KRD VS KTD FOLLOWED BY K MAINTENANCE OR CONTROL

EHA Library, Heinz Ludwig, 294878

CHARACTERIZATION OF RELAPSE AND SECOND-LINE THERAPY IN LENALIDOMIDE-REFRACTORY PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: A PHASE 3 FIRST TRIAL SUBANALYSIS

EHA Library, Salomon Manier, 294879

ESTIMATING THE NUMBER OF US PATIENTS WITH MULTIPLE MYELOMA AT DIFFERENT LINES OF TREATMENT

EHA Library, Feng Wang, 294880

EFFICACY OF MAINTENANCE AND CONTINUOUS THERAPY IN PATIENTS WITH UNTREATED MULTIPLE MYELOMA: INDEPENDENT NETWORK META-ANALYSIS

EHA Library, Alexander Luchinin, 294881

NUMERIC ABNORMALITIES OF 1Q21 IDENTIFY AN ULTRA HIGH RISK GROUP OF MYELOMA PATIENTS

EHA Library, Magdalini Migkou, 294882

EVALUATION OF MINIMAL RESIDUAL DISEASE (MRD) BY NEXT GENERATION SEQUENCING (NGS) AND MASS SPECTROMETRY (MS) IN PHASE II TRIALS OF NEWLY-DIAGNOSED MULTIPLE MYELOMA (NDMM)

EHA Library, Jagoda Jasielec, 294883

GLOBAL RATES OF INFLUENZA (FV) AND PNEUMOCOCCAL (PV) VACCINATION IN MULTIPLE MYELOMA (MM) PATIENTS (PTS) IN INSIGHT MM: IMPACT ON HEALTHCARE RESOURCE UTILIZATION (HRU) AND OVERALL SURVIVAL (OS)

EHA Library, Michael A. Thompson, 294884

THE ROLE OF AGE >80 IN DEFINING FRAIL PATIENTS: AN ANALYSIS FROM THE IMWG FRAILTY SCORE COHORT

EHA Library, Mattia D'Agostino, 294885

MATCHING-ADJUSTED INDIRECT COMPARISONS OF EFFICACY OUTCOMES FOR IDECABTAGENE VICLEUCEL FROM THE KARMMA STUDY VS SELINEXOR PLUS DEXAMETHASONE (STORM PART 2) AND BELANTAMAB MAFODOTIN (DREAMM-2)

EHA Library, Paula Rodríguez-Otero, 294886

DREAMM-2: SINGLE-AGENT BELANTAMAB MAFODOTIN IN RELAPSED/REFRACTORY MULTIPLE MYELOMA REFRACTORY TO PROTEASOME INHIBITORS, IMMUNOMODULATORY AGENTS, AND REFRACTORY AND/OR INTOLERANT TO ANTI-CD38 MABS

EHA Library, Sagar Lonial, 294887

CHARACTERISTICS, TREATMENT PATTERNS, AND OUTCOMES AMONG PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA IN EUROPE

EHA Library, Boris Gorsh, 294888

MASS SPECTROMETRY FREE LIGHT CHAIN ASSESSMENT FOR COMPREHENSIVE MONOCLONAL PROTEIN EVALUATION DURING MYELOMA MONITORING

EHA Library, Ellen Jenner, 294889

DARATUMUMAB WITH IXAZOMIB AND DEXAMETHASONE IN MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED PRIOR TREATMENT WITH A LENALIDOMIDE-BASED REGIMEN: DESIGN AND FIRST RESULTS OF THE PHASE 2 DARIA STUDY

EHA Library, Evangelos Terpos, 294890

IFM 2012-03 FINAL ANALYSIS, CARFILZOMIB MAINTENANCE FOR NON-TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA

EHA Library, Arthur Bobin, 294891